Ignite Creation Date:
2025-12-24 @ 11:14 PM
Ignite Modification Date:
2025-12-25 @ 8:49 PM
Study NCT ID:
NCT04556669
Status:
UNKNOWN
Last Update Posted:
2021-05-27
First Post:
2020-09-06
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Anti-PD-L1 Armored Anti-CD22 CAR-T/CAR-TILs Targeting Patients With Solid Tumors
Sponsor:
Hebei Senlang Biotechnology Inc., Ltd.
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2020-08-01
Start Date Type:
ACTUAL
Primary Completion Date:
2023-08-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-08-01
Completion Date Type:
ESTIMATED
First Submit Date:
2020-09-06
First Submit QC Date:
None
Study First Post Date:
2020-09-21
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2021-05-25
Last Update Post Date:
2021-05-27
Last Update Post Date Type:
ACTUAL